El interés en corto de Sangamo Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Sangamo Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Sangamo Therapeutics (NASDAQ:SGMO) Bolsa, Informe de interés en corto

Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.2% on Tuesday.
The Dow traded up 0.08% to 42,963.84 while the NASDAQ gained 0.18% to 18,573.16. The S&amp;P 500, however, fell 0.02% to 5,852.75 during the session.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.8% on Tuesday.
In trading on Monday, industrials shares fell by 1%.
Top Headline
Shares of Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) fell around 5% on Tuesday after it reported fiscal third-quarter results.
Its sales growth was flat year over year, reaching $33.33 billion, marginally missing the analyst consensus estimate of $33.43 billion. Service and other revenue growth was offset by declines in wireless equipment revenue. Adjusted EPS of $1.19 beat the analyst consensus estimate of $1.18.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) shares shot up 22% to $75.59 after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes made to the Zio AT device.</li>
<li>Shares of Mueller Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) got a boost, surging 16% to $83.35 after the company reported better-than-expected third-quarter sales results.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 37% to $1.2499 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) shares dropped 19% to $115.37 after the company reported mixed third-quarter financial results and cut its FY24 EPS below estimates.</li>
<li>Shares of Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) were down 8% to $73.50 after the company reported worse-than-expected third-quarter EPS and sales and cut its 2024 guidance.</li>
<li>Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) was down, falling 8% to $84.04 following second-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $72.06 while gold traded up 0.8% at $2,761.40.
Silver traded up 2.9% to $35.050 on Tuesday, while copper rose 0.7% to $4.3890.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.21%, Germany's DAX fell 0.20% and France's CAC 40 fell 0.01%. Spain's IBEX 35 Index fell 0.07%, while London's FTSE 100 fell 0.14%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
The composite manufacturing index in the US Fifth District came in at -14 for October compared to a reading of -21 in the prior month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

IRTC

LOGI

SGMO

Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results

Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of <a href="https://www.benzinga.com//node/41449489">Fabry disease</a>.
What To Know: The FDA&#8217;s approval of the accelerated pathway was based on data from the ongoing Phase 1/2 STAAR study. Without an accelerated pathway, the company would have to conduct an additional study. Tuesday&#8217;s announcement will allow Sangamo to forego the extra study, speeding up the estimated time to potential approval by approximately three years.
The data from the ongoing study showed promising safety and efficacy results and evidence of improved kidney function. These improvements, particularly in estimated glomerular filtration rate (eGFR), an indicator of kidney function, suggest the potential to address the renal complications commonly seen in Fabry disease.
&#8220;Fabry is a debilitating disease, for which there is a serious unmet medical need,&#8221; said Sandy Macrae, CEO of Sangamo. 
&#8220;I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated&#8221;.
Sangamo said it has begun to execute Biologics License Application (BLA) readiness activities and expects to submit a BLA during the second half of 2025.
See Also: <a href="https://www.benzinga.com/news/24/10/41415824/lucid-ceo-peter-rawlinson-talks-saudi-investment-elon-musks-political-views-and-taking-business-from">Lucid CEO Peter Rawlinson Talks Saudi Investment, Elon Musk&#8217;s Political Views And Taking Business From Tesla</a>
How To Buy Sangamo Therapeutics Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Sangamo Therapeutics's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
SGMO Price Action: At the time of writing, Sangamo shares are up 33.7% at $1.21, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of Sangamo Therapeutics.

News

Movers

What's Going On With Sangamo Therapeutics Shares Tuesday?

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.
The Dow traded down 0.09% to 42,891.94 while the NASDAQ slipped 0.28% to 18,488.16. The S&amp;P 500 also fell, dropping, 0.30% to 5,836.28.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Energy shares rose by 0.5% on Tuesday.
In trading on Monday, industrials shares fell by 1.1%.
Top Headline
3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported better-than-expected third-quarter adjusted EPS and sales and revised FY24 EPS guidance.
The company reported net sales of $6.294 billion, a slight increase of 0.4% year-over-year. Adjusted net sales totaled $6.068 billion, up 1.5% on year and marginally beating the consensus of $6.057 billion. Adjusted EPS was $1.98, up 18% Y/Y, beating the consensus of $1.90.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) shares shot up 20% to $74.21 after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes made to the Zio AT device.</li>
<li>Shares of Mueller Industries, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) got a boost, surging 16% to $83.91 after the company reported better-than-expected third-quarter sales results.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 40% to $1.2787 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) shares dropped 20% to $114.60 after the company reported mixed third-quarter financial results and cut its FY24 EPS below estimates.</li>
<li>Shares of Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) were down 11% to $71.71 after the company reported worse-than-expected third-quarter EPS and sales and cut its 2024 guidance.</li>
<li>Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) was down, falling 10% to $83.01 following second-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 2.8% to $72.54 while gold traded up 0.5% at $2,753.70.
Silver traded up 2.4% to $34.900 on Tuesday, while copper rose 0.3% to $4.3745.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.21%, Germany's DAX fell 0.20% and France's CAC 40 fell 0.01%. Spain's IBEX 35 Index fell 0.07%, while London's FTSE 100 fell 0.14%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
The composite manufacturing index in the US Fifth District came in at -14 for October compared to a reading of -21 in the prior month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

Crude Oil Rises Sharply; 3M Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 120.0% to $0.45 during Tuesday's regular session. The company's market cap stands at $6.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 102.48% to $0.45. The market value of their outstanding shares is at $8.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares rose 90.15% to $2.87. The company's market cap stands at $7.4 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 41.29% to $1.29. The company's market cap stands at $268.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 31.15% to $3.45. The market value of their outstanding shares is at $27.5 million. </li>
<li>Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) shares increased by 28.61% to $3.67. The market value of their outstanding shares is at $160.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 30.5% to $0.33 during Tuesday's regular session. The market value of their outstanding shares is at $23.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock fell 28.74% to $0.94. The company's market cap stands at $2.7 million. </li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) stock decreased by 19.52% to $6.17. The company's market cap stands at $336.1 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock decreased by 17.86% to $1.84. The market value of their outstanding shares is at $28.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares decreased by 17.15% to $5.22. The company's market cap stands at $3.4 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 16.65% to $0.65. The market value of their outstanding shares is at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIVI

ENSC

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HOWL

INAB

ISPC

NDRA

SNSE

VSEE

VYGR

12 Health Care Stocks Moving In Tuesday's Intraday Session

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 150 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.38% to 42,768.98 while the NASDAQ slipped 0.43% to 18,459.79. The S&amp;P 500 also fell, dropping, 0.49% to 5,825.05.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.1% on Tuesday.
In trading on Monday, consumer discretionary shares fell by 0.9%.
Top Headline
General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reported better-than-expected third-quarter results.
Quarterly adjusted earnings per share of $2.96 beats the street view of $2.43. Quarterly sales of $48.757 billion (+10.5%) beat the analyst consensus estimate of $44.585 billion.
The company raised 2024 adjusted EPS guidance from $9.50 – $10.50 to $10.00 – $10.50 (consensus $10.00).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares shot up 153% to $3.8400.</li>
<li>Shares of Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) got a boost, surging 144% to $0.5015</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 50% to $1.3663 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares dropped 29% to $0.9370.</li>
<li>Shares of JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) were down 25% to $1.67.</li>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) was down, falling 24% to $0.3598.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded up 0.6% at $2,754.70.
Silver traded up 2% to $34.760 on Tuesday, while copper rose 0.8% to $4.3940.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.1% and France's CAC 40 fell 0.2%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 fell 0.2%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

JCSE

Dow Falls Over 150 Points; General Motors Tops Q3 Views

WIIM

Sangamo Therapeutics shares are trading higher after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.

Sangamo Therapeutics Announces Alignment With FDA On Accelerated Approval Pathway For ST-920 In Fabry Disease, BLA Submission Expected In 2025

On Friday, the FDA approved Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)&nbsp;Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency), or hemophilia B (congenital factor IX deficiency).
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41296235/u-s-fda-approves-pfizers-hympavzi-marstacimab-hncq-for-the-treatment-of-adults-and-adolescents-wit" rel="noreferrer noopener">auto-injector pen</a>.
Hympavzi can offer a subcutaneous treatment option with a once-weekly dosing schedule and minimal preparation required for each individual administration.
Hemophilia is a family of rare genetic blood diseases caused by a clotting factor deficiency (FVIII in hemophilia A, FIX in hemophilia B), impacting more than 800,000 people globally.
Results from the Phase 3 BASIS trial (<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03938792&amp;esheet=54134066&amp;newsitemid=20241009505480&amp;lan=en-US&amp;anchor=NCT03938792&amp;index=1&amp;md5=2f50558fdab1e48356374ad447cabc38" rel="noreferrer noopener">NCT03938792</a>) supported the FDA approval of Hympavzi.
In the study, Hympavzi reduced the annualized bleeding rate (ABR) for treated bleeds by 35% and 92% after a 12-month active treatment period compared to routine prophylaxis (RP) and on-demand (OD) treatment, respectively, in patients with hemophilia A or B without inhibitors.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion&nbsp;for marstacimab for the routine prophylaxis of bleeding episodes in adults and adolescents with severe hemophilia A or hemophilia B.
Reuters, citing some analysts, highlights that Hympavzi sales are expected to reach $300 million by 2030.
Earlier this year, FDA approved&nbsp;Pfizer&#8217;s Beqvez (fidanacogene&nbsp;elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that&nbsp;are often administered&nbsp;multiple times a week or&nbsp;multiple&nbsp;times a month.
In July, Pfizer, in collaboration with Sangamo Therapeutics Inc, released results from the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for adult patients with moderately&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39937203/sangamo-stock-spikes-as-pfizer-partnership-meets-goal-in-late-stage-study" rel="noreferrer noopener">severe to severe hemophilia A</a>.
Price Action: PFE stock is down 0.14% at $29.12 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41297538/amazons-ai-driven-aws-growth-to-power-outperformance-analysts" target="_blank" rel="noreferrer noopener">Amazon&#8217;s AI-Driven AWS Growth To Power Outperformance: Analysts</a>.</li>
</ul>

Biotech

Large Cap

Health Care

Media

General

FDA Approves Pfizer's Second Hemophilia Drug With Six Months

It&nbsp;expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately&nbsp;$13 million, impairment expense of approximately&nbsp;$6 million, and depreciation and amortization of approximately&nbsp;$7 million, in the range of approximately&nbsp;$125 million&nbsp;to&nbsp;$145 million&nbsp;in 2024.

Guidance

Sangamo Therapeutics Expects FY24 GAAP Basis Total Operating Expenses Of Approximately $150M - $170M

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $356.000 thousand which missed the analyst consensus estimate of $8.260 million by 95.69 percent. This is a 94.79 percent decrease over sales of $6.835 million the same period last year.

Earnings Misses

Sangamo Therapeutics Q2 2024 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $356.000K Miss $8.260M Estimate

Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for <a href="https://www.benzinga.com/pressreleases/24/08/b40185649/sangamo-therapeutics-announces-global-epigenetic-regulation-and-capsid-delivery-license-agreement-">neurodegenerative diseases.&nbsp;</a>
The Details:
Sangamo has granted Genentech an exclusive license to its proprietary zinc finger repressors and neurotropic adeno-associated virus (AAV) capsid, STAC-BBB. Under the terms of the agreement, Genentech is expected to pay Sangamo $50 million in near-term upfront license fees and milestone payments. Sangamo is eligible to earn up to $1.9 billion in development and commercial milestones spread across multiple potential products under the agreement and tiered royalties on net sales of such products.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/08/40167450/whats-going-on-with-intel-stock-today">What&#8217;s Going On With Intel Stock Today?</a>
"Sangamo has been pioneering the field of genomic medicine for years to address devastating neurodegenerative diseases with limited current treatment options,&#8221; said Sandy Macrae, CEO of Sangamo. &#8220;We are excited to share this powerful combination with Genentech to advance potential treatment options for devastating neurodegenerative disorders, and we are hopeful this could be the first of multiple capsid collaborations to come with other partners.&#8221; 
<h2 class="wp-block-heading">How To Buy SGMO Stock: </h2>
By now you're likely curious about how to participate in the market for Sangamo Therapeutics &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Sangamo Therapeutics, which is trading at $1.19 as of publishing time, $100 would buy you 84.03 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
SGMO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Sangamo Therapeutics shares are up 59% at $1.22 at the time of publication Tuesday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40171977/hims-hers-health-reports-better-than-expected-q2-results-details">Hims &amp; Hers Health Reports Better-Than-Expected Q2 Results: Details</a></li>
</ul>
Image: Shutterstock

Penny Stocks

Why Sangamo Therapeutics Stock Is Soaring

Sangamo shares are trading higher after the company entered into a license agreement with Genentech to develop intravenously administered genomic medicines for neurodegenerative diseases. Sangamo is expected to receive $50 million in near-term upfront license fees and is eligible for up to $1.9 billion in milestones.

Sangamo Enters License Agreement With Genentech To Develop Intravenously Administered Genomic Medicines For Neurodegenerative Diseases; Co. Expected To Receive $50M In Near-Term Upfront License Fees And Is Eligible For Up To $1.9B In Milestones

Shares of Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SAIA/earnings">second-quarter financial results</a>.
Saia reported quarterly earnings of $3.83 per share which missed the analyst consensus estimate of $4.00 per share. The company reported quarterly sales of $823.24 million which missed the analyst consensus estimate of $826.55 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Saia shares dipped 18.6% to $398.01 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 117.4% to $0.4639 after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares jumped 101.3% to $6.67 after the company filed a request for the withdrawal of its registration statement on a Form S-1.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 53% to $13.94.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares gained 46.2% to $10.83 after the company beat second-quarter earnings estimates.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares climbed 43.3% to $8.84. Carbon Revolution said it will supply the carbon fiber wheels available on the just-revealed Chevrolet Corvette ZR1.</li>
<li>Everi Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) rose 41.1% to $12.93 after it entered an agreement to be acquired by funds managed by Apollo affiliates for $14.25 per share in cash.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 37% to $4.45.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) jumped 36.6% to $8.66 on better-than-expected second-quarter earnings and raising FY24 outlook.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 35% to $0.9043.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) rose 28% to $1.55 after the company announced results from a bias analysis conducted for its concluded Phase 3 study of Multikine. Multikine cut the 5-year risk of death by half compared to control in its target population.</li>
<li>AudioEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) rose 25% to $24.52 following second-quarter results.</li>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) gained 24.4% to $1.1760. Pineapple Financial CSO Christa Lillian Mitchell bought a total of 2,000 shares at an average price of $0.88.</li>
<li>Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) climbed 23% to $1.66.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) rose 19% to $6.71.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) rose 17.6% to $65.16.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) jumped 17% to $368.65 after the company reported better-than-expected second-quarter financial results.</li>
<li>Mohawk Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) gained 16.5% to $156.70 following mixed second-quarter earnings.</li>
<li>Karooooo Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) gained 16% to $33.40. Karooooo announced termination of secondary public offering of ordinary shares due to market conditions.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) climbed 15% to $118.99 after better-than-expected second-quarter financial results and FY24 EPS outlook raise.</li>
<li>International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) gained 13.4% to $22.86 after the company entered an agreement for its Gaming &amp; Digital business to be acquired by funds managed by affiliates of Apollo.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) rose 12.1% to $1.76.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) rose 11% to $15.06.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) surged 11% to $25.32 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) gained 10.7% to $246.86 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares gained 10.4% to $0.0415 after falling over 17% on Thursday.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) rose 9% to $20.58. Viasat announced new reporting segment structure.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares gained 8.7% to $914.71 as the company reported better-than-expected results for the first quarter. The company said it still expects net sales to increase approximately 10% year-over-year in fiscal year 2025 to $4.7 billion.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) climbed 7.6% to $48.69 following strong second-quarter earnings and increased 2024 guidance.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) climbed 7.6% to $72.55 following better-than-expected second-quarter financial results and increased 2024 guidance.</li>
<li>Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) rose 7.4% to $25.98 after the company reported better-than-expected quarterly earnings results. Also, multiple firms raised their respective price targets on its stock.</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) gained 6.8% to $319.30 after the company reported better-than-expected quarterly revenue results.</li>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) shares gained 4.7% to $47.26 following better-than-expected quarterly results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares dipped 59.6% to $0.7830 after the company reported pricing of $3.5 million underwritten public offering.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) fell 46.9% to $0.2603.</li>
<li>Nature&#8217;s Miracle Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) fell 46.4% to $0.2099 after the company announced pricing of $1.2 million public offering.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 40.7% to $63.97 after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) fell 29.6% to $1.3150. Predictive Oncology announced exercise of warrants for $1.26 million gross proceeds.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) declined 29.2% to $1.5006 as the company reported top-line data from its Phase 1a Alzheimer&#8217;s trial and announced up to $122.7 million private placement financing.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) dipped 26.1% to $1.53</li>
<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) fell 23.8% to $0.2751.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares declined 23.2% to $0.3188 after reporting fourth-quarter results.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) fell 20.2% to $1.30.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) declined 20.1% to $1.6299.</li>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares fell 18.9% to $8.27 after the company reported worse-than-expected second-quarter financial results.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) declined 17.6% to $1.24.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares dipped 13.4% to $1.1250 after the company announced a proposed public offering of common shares.</li>
<li>BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) fell 12.6% to $32.53 following quarterly results.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) declined 11.8% to $135.36 following a first-quarter earnings miss and soft EPS guidance.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares fell 11.2% to $4.40 after gaining 3% on Thursday.</li>
<li>Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) fell 9.1% to $25.67.</li>
<li>World Acceptance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) dipped 7.8% to $134.62 following weak quarterly sales.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) fell 7.4% to $25.61.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) shares declined 7.2% to $44.56 following a second-quarter earnings miss.</li>
<li>Carter&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares fell 6.6% to $55.87 following weak quarterly sales.</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) declined 6.3% to $213.01 after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares fell 6% to $38.18. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) declined 4.6% to $232.05 following second-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39984491/nvidia-lockheed-martin-and-2-other-stocks-insiders-are-selling">Nvidia, Lockheed Martin And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

COUR

CREV

DECK

DOUG

DXCM

EVRI

FWRD

GROM

KARO

KITT

LBRDA

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WINT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session

Sangamo Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NYSE">SGMO</a>) short percent of float has fallen 17.95% since its last report. The company recently reported that it has 12.73 million shares sold short, which is 6.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sangamo Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721938510_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sangamo Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sangamo Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sangamo Therapeutics's peer group average for short interest as a percentage of float is 7.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Sangamo Therapeutics's Recent Short Interest

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 100 points on Wednesday.
The Dow traded down 0.82% to 40,025.48 while the NASDAQ fell 2.92% to 17,472.06. The S&amp;P 500 also fell, dropping, 1.84% to 5,453.67.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39932485/jim-cramer-calls-axsome-a-double-or-nothing-stock-says-sap-is-incredible">Jim Cramer Calls Axsome A &#8216;Double Or Nothing Stock,&#8217; Says SAP Is &#8216;Incredible&#8217;</a> 
Leading and Lagging Sectors Utilities shares jumped by 0.8% on Wednesday.
In trading on Wednesday, consumer discretionary shares fell by 3%.
Top Headline
Shares of AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) rose around 5% during Wednesday&#8217;s session following second-quarter earnings.
AT&amp;T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Pieris Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) shares shot up 78% to $14.15 after the company announced that the company entered into a definitive merger agreement with Palvella Therapeutics.</li>
<li>Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) got a boost, surging 47% to $0.5914 after licensing partner Pfizer&#8217;s Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec met its primary endpoint.</li>
<li>PROG Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRG#NYSE">PRG</a>) shares were also up, gaining 21% to $42.02 after the company reported better-than-expected second-quarter financial results. Also, the company raised its FY24 guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares dropped 76% to $1.1899 after the company announced the pricing of a $10 million public offering of 6,665,000 common shares and Class A warrants at $1.50 per share.</li>
<li>Shares of Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) were down 40% to $2.49 after the company announced the pricing of a $2 million public offering of 469,340 common shares at $4.24 a share.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) was down, falling 28% to $56.37 after the company reported worse-than-expected quarterly financial results. Also, the company issued its FY25 EPS guidance below estimates.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39929121/top-3-tech-and-telecom-stocks-that-are-set-to-fly-in-july">Top 3 Tech And Telecom Stocks That Are Set To Fly In July</a> 
Commodities In commodity news, oil traded up 1% to $77.72 while gold traded up 0.4% at $2,417.40.
Silver traded up 0.1% to $29.35 on Wednesday, while copper fell 1.2% to $4.1110.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.61%, Germany's DAX fell 0.92% and France's CAC 40 fell 1.12%. Spain's IBEX 35 Index fell 0.02%, while London's FTSE 100 fell 0.17%.
The HCOB Eurozone manufacturing PMI declined to 45.6 in July from 45.8 in June, while services PMI slipped to 51.9 from 52.8. The HCOB France composite PMI climbed to 49.5 in July from 48.8 in the prior month, while German composite PMI declined to 48.7 from 50.4.
The S&amp;P Global Flash UK manufacturing PMI rose to 51.8 in July from 50.9 in June, while services PMI rose to 52.4 in July from 52.1 in the previous month.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei 225 falling 1.11%, Hong Kong's Hang Seng Index falling 0.91%, China's Shanghai Composite Index declining 0.46% and India's S&amp;P BSE Sensex declining 0.35%.
The HSBC India Manufacturing PMI climbed to 58.5 in July from 58.3 the prior month, while services PMI rose to 61.1 in July from 60.5. The au Jibun Bank Flash Japan composite PMI rose to 52.6 in July versus a final reading of 49.7 in June.
Economics
<ul>
<li>U.S. mortgage applications declined by 2.2% in the latest week, compared to a 3.9% gain in the prior period.</li>
<li>The S&amp;P Global flash manufacturing PMI fell to 49.5 in July from 51.6 in June and compared to market estimates of 51.7.</li>
<li>The S&amp;P Global composite PMI climbed to 55.0 in July from 54.8 in the prior month.</li>
<li>The U.S. trade deficit in goods shrank to $96.84 billion in June versus a $99.37 billion gap in the earlier month.</li>
<li>Building permits increased by 3.9% to an annual rate of 1.454 million in June.</li>
<li>U.S. new home sales declined 0.6% month-over-month to an annualized rate of 617,000 in June.</li>
<li>The EIA said crude oil inventories in the U.S. declined by 3.741 million barrels in the week ended July 19, compared to market estimates of a 2.05 million decline.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/07/39932008/tesla-to-rally-around-22-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday</a>

AZTR

NUWE

PIRS

Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating on July 31. Ritu Baral's rating is based on a va...

Strategic Partnerships and Clinical Success: A Buy Rating for Sangamo Biosciences

In a report released today, Gena Wang from Barclays maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report), with a price target of...

Barclays Sticks to Their Buy Rating for Sangamo Biosciences (SGMO)

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), with a price t...

Sangamo Biosciences: Hold Rating Amid Financial Challenges and Clinical Progress

Tenax Therapeutics, Sangamo Therapeutics, and VSee Health are the 3 Penny Stocks to watch on August 8, based on&nbsp;TipRanks' Penny Stock Screener...

3 Penny Stocks to Watch Now, 8/8/24

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

Strong Buy Recommendation for Sangamo Biosciences Amidst Strategic Partnerships and Promising Gene Therapy Advancements

An update from Sangamo Biosciences ( ($SGMO) ) is now available. Facing a class action complaint challenging the validity of their Common Stock Inc...

Sangamo Therapeutics Seeks Court Approval for Stock Amendment

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Iso-Vec... Trifecta Soon?

Sangamo (SGMO) announced the outcome of a recent interaction with the FDA, providing a clear regulatory pathway to accelerated approval for isaralg...

Sangamo announces alignment with FDA on ST-920 accelerated approval pathway

Unusual total active option classes on open include: Energy Vault Holdings (NRGV), Sangamo (SGMO), Nordstrom (JWN), Philip Morris (PM), Verizon (VZ...

Unusually active option classes on open October 22nd

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) and keeping the price target ...

Accelerated Approval Path Boosts Sangamo Biosciences' Outlook: Buy Rating Reiterated

ASPN

BMRN

CORZ

NRGV

NVSEF

RHHBF

RHHBY

RHHVF

SNYNF

TENX

VRTX

Press Releases

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

Comments

Sangamo Therapeutics

Interés en corto

Sangamo Therapeutics (NASDAQ:SGMO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL